Skip to content

Educational reference only. Not medical advice, diagnosis, or treatment, and not dosing, injection, or purchasing guidance.Medical disclaimer

Melanotan II

These sentences are taken from FDA’s compounding-risk page and, where noted, the July 2026 advisory-committee agenda. They are not a finding that a substance works.

  • Melanotan II is on the withdrawn-nomination list. FDA says compounded drugs containing it may pose an immunogenicity risk for certain routes because of aggregation or peptide-related impurities.
  • FDA says published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. This page does not re-read those case reports and does not give frequencies.

Legal effect beyond the words on those pages is not interpreted. No animal or human study is summarized, because none was opened.

This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.

Page record

  • Type: Compound
  • Domain: peptides
  • Evidence: Not rated
  • Status: reviewed
  • Last reviewed: 2026-11-20

Sources

Referenced by

A link from another wiki page is not evidence. Facts should point at the sources above.